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We used a multiplexed fluorescent microsphere 
immunoassay lo develop a sandwich capture assay to 
assess simultaneously the production o f  thymus helper 
(TH) 1- and TH2-type cytokines in tissue culture 
supernatant obtained from  stimulated peripheral blood 
mononuclear cells. The assay then was used to assess 
the cytokine production o f  patients with 
hyperimmunoglobulinemia E  syndrome and in cord 
blood from  neonates. The multiplexed assay has a 
reportable range o f  less them 10 to 50,000 pg/mL. For 
linearity and recovery studies, R 2 values fo r  the 6 
cytokines ranged from  0.988 lo 0.999fo r  samples 
spiked with known concentrations o f  recombinant 
cytokine standards and fo r  patient samples. The assay 
showed good specificity, with little cross-reactivity 
between cytokines. Results from  supematants o f  
Staphylococcus aureus -stim ulated peripheral blood 
mononuclear cells obtained from  6 patients with 
hyperimmunoglobulinemia E  syndrome showed 
significantly less interferon (IFN)-gamma production 
than cells from  healthy control subjects. Cord blood 
cells from  neonates produced significantly less 
interleukin 12 and IFN-gamma than cells from  adults in 
group B streptococci-stimulated mononuclear cells.
The fluorescent multiplexed microsphere immunoassay 
can be used to quantitate multiple cytokines from  1 
sample and should be useful fo r  further understanding 
o f  the cytokine role in disease.
Cytokines are produced by a variety of different cell 
types and are important immunoregulators in the processes of 
inflammation, hematopoiesis, and wound healing. Individual 
cytokines can have multiple effects on the growth and differ­
entiation of many cell types and may exhibit considerable 
overlap with other cytokines in their biologic effects on these 
cells. The analysis and quantitation of cytokines in biologic 
fluids and tissue culture supernatant have become widely 
used in research, constitute an emerging field of interest in 
clinical laboratory medicine, and clearly are important in 
furthering our understanding of many immunologic and 
inflammatory disorders.
In patients with recurrent or severe infections, the possi­
bility of an underlying immunodeficiency should be consid­
ered. Although many factors are involved, several studies 
have shown that decreased or defective cytokine production 
may have a role in immunologic disorders such as common 
variable immunodeficiency and hyperimmunoglobulinemia E 
syndrome.1'2 Common variable immunodeficiency involves a 
B-cell defect in the maturation and differentiation process 
from hematopoietic stem cells to plasma cells and their secre­
tion of immunoglobulins. It is characterized by markedly 
decreased serum immunoglobulin levels, normal or nearly 
normal numbers of circulating immunoglobulin-bearing 
mature B cells, impaired antibody responses, and recurrent 
bacterial infections of the sinopulmonary tract.3'4 These B- 
cell defects often can be associated with deficient secretion of 
interferon (IFN)-gamma or interleukin (IL)-2.5 The hyperim­
munoglobulinemia E syndrome and associated recurrent 
infections involve a neutrophil chemotaxis disorder that may 
be associated with altered T-cell activity and allergic media­
tors. Patients with chemotactic disorders have manifestations
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of recurrent cutaneous abscesses, mucocutaneous candidi­
asis, and severe pneumonia.6 Borges et al2 and Del Prete et 
al7 have reported deficient production of IFN-gamma in 
patients with this disorder. Also included in the present study 
were group B streptococci-stimulated mixed mononuclear 
cells obtained from umbilical cord blood of 8 newborns. 
Neonates have defects in neutrophil function and are defi­
cient in the production of the phagocyte activator IFN- 
gamma and 1L-12, a major enhancer of IFN-gamma.840
The optimal manner in which to correlate a specific 
disease process with changes in cytokine levels requires 
analyzing each sample for multiple cytokines. The most 
common method for the quantitation of secreted cytokines is 
the enzyme-linked immunosorbent assay (ELISA). Assays 
fo r a variety  o f  cy tok ines are read ily  availab le from  
numerous commercial vendors. While ELlSAs show good 
sensitivity and specificity, they have many drawbacks in 
assaying a panel of multiple cytokines in 1 sample. Each 
ELISA can measure only 1 cytokine per well and requires up 
to 200 nL of sample per test. When attempting to assay 6 or
7 cytokines, sample volume limitations become an issue, 
especially when working with tissue culture supernatant. 
Even with assays from the same manufacturer, sample dilu­
tions, labeled antibodies, and incubation times vary greatly 
between tests, making it difficult to run several assays at 
once. Since cytokine production by patients’ cells varies 
greatly, the dynamic range of only 2 to 3 logs of the ELlSAs 
requires that many samples must be diluted and retested. By 
using a multiplexed fluorescent microsphere immunoassay 
system (Luminex, Luminex, Austin, TX), we developed a 
sandwich capture assay to simultaneously assess the produc­
tion of THl-type (IFN-gamma, IL-2, and 1L-12) and TH2- 
type (1L-4,1L-6, and 1L-10) cytokines in tissue culture super­
natant obtained from stimulated mononuclear cells.
The Luminex M ulti-Analyte Profiling technology is 
based on microscopic polystyrene particles called micro­
spheres that are labeled internally with 2 different fluo- 
rophores. When excited by a 635-nm laser, the fluorophores 
emit at different wavelengths, 658 nm and 712 nm. By 
varying the 658:712 emission ratios, an array of up to 100 
different fluorescent profiles have been created. By using 
precision fluidics, digital signal processors, and advanced 
optics, the Luminex 100 analyzer classifies each microsphere 
according to its predefined fluorescent emission ratio. Thus, 
multiple microspheres coupled to different analytes can be 
combined with a single sample and assayed. A third fluo- 
rophore coupled to a reporter molecule allows quantitation of 
the analyte that has bound to the microsphere surface.
In this report, we describe the development and valida­
tion of this system for the simultaneous quantification of 6 
cytokines in tissue culture supernatant. The clinical useful­
ness of the assay was demonstrated by analyzing TH1- and
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TH2-type cytokine responses by the mononuclear cells of 
patients w ith im m unodeficiency syndrom es previously 
reported to have depressed or defective cytokine produc­
tion. We also assessed the cytokine production by stimu­
lated mixed mononuclear cells from neonates, which have 
been shown to be deficient in the production of IFN-gamma 
and IL-12.
M a t e r i a l s  a n d  M e t h o d s
Clinical Samples
Samples included supernatants from Staphylococcus  
awra/s-stimulated peripheral blood mononuclear cells of 6 
patients with hyperim m unoglobulinem ia E syndrome, 1 
patient with common variable immunodeficiency, and 12 
healthy control subjects. Also included in this study were 
supernatants from group B streptococci-stimulated mixed 
m ononuclear cells from the cord blood of 8 newborns 
compared with group B streptococci-stimulated peripheral 
blood mononuclear cells from 8 healthy adults.
All patient samples included in the study had been used 
in  prev ious cy tok ine stud ies that w ere review ed and 
approved institutionally.
Tissue Culture Supernatants
Peripheral blood mononuclear cells and mixed mononu­
clear cell supernatants were derived from standard tissue 
cu lture lym phocyte p ro life ra tio n  a ssa y s .11-14 Briefly , 
lymphocytes were obtained from anticoagulated peripheral 
blood by Ficoll-Paque density gradient centrifugation. The 
cells then were counted on a hemocytometer and adjusted to 
a concentration of 1 x 106/mL. Cell cultures were set up in 
96-well microtiter plates in RPM1 1640 medium containing 
1 0 % heat-inactivated pooled normal human serum, antibiotic 
antimycotic, and L-glutamine. Mitogens (phytohemagglu­
tinin, concanavalin A, pokeweed mitogen) and antigens 
(heat-killed S aureus and group B streptococci) were added 
in varying concentrations. Cultures were incubated at 37°C 
with 5% carbon dioxide for 24-, 48-, and 72-hour intervals. 
After incubation, instead of labeling the cells with tritiated 
thymidine as in standard proliferation assays, the cells were 
centrifuged, and the supernatants were removed, divided into 
aliquots, and stored at -70°C  until assayed for cytokine 
content.
Coupling of the Microspheres
For the developm ent of the m ultiplexed panel of 6 
cytokines, monoclonal antibodies to human IL-2, 1L-4, 1L-6, 
IL-10 (BD Biosciences, San Diego, CA), IL-12 (R&D Systems, 
M inneapolis, M N), and IFN -gam m a (Pierce-Endogen,
Am J Clin Pathol 2002; 118:346-353 3 4 7
M a r t in s  e t  a l  / Multiplex Assay Cytokine Responses
Rockford, IL) were used as capture antibodies. The mono­
clonal antibodies were diluted in phosphate-buffered saline 
(PBS), pH 7.2, to a concentration of 50 ng/mL and cova­
lently coupled to carboxylated Luminex microspheres using 
a 2-step carbodiimide reaction.15 Carboxylated microspheres 
were activated for 20 minutes at a concentration of 6.25 x 
106/mL in PBS, pH 6.1, with 5 mg/mL of 1-ethyl-3-( 3- 
dimethylaminopropyl) carbodiimide (EDC) and iV-hydroxy- 
sulfosuccinimide (sulfo-NHS) (Pierce-Endogen). Activated 
microspheres then were washed with PBS, pH 7.2, followed 
by centrifugation and incubated with the previously 
described monoclonal antibodies for 1 hour at room temper­
ature on a rocker. The coupled microspheres then were 
washed twice with PBS, pH 7.2, + 0.05% polysorbate 
(Tween) 20 (PBST) and resuspended in 1 inL of PBS, pH 
7.2, with 0.1% bovine serum albumin and 0.05% sodium 
azide (PBSB). The microspheres then were incubated for 30 
minutes on a rocker to permit blocking of the unreacted sites 
and stored at 4°C. in PBSB. Since the fluorescent dyes 
contained with the microspheres are light-sensitive, all acti­
vation, centrifugation, and incubation steps were done in the 
dark. Other measures to reduce light exposure, such as wrap­
ping the reaction microtubes in foil and turning off unneces­
sary light sources, also were used.
Multiplexed Cytokine Assay
A standard curve for each cytokine was made by mixing 
known concentrations of recombinant human cytokines IL-4, 
1L-6,1L-10 (BD Biosciences), 1L-2,1L-12 (R&D Systems), 
and IFN-gamma (Pierce-Endogen) in RPMI 1640 medium. 
By making 1:5 dilutions in RPMI medium from 50,000 to 0 
pg/mL (medium only), an 8-point standard curve was gener­
ated. Each standard was run in duplicate. In addition, 3 
controls containing high (5,000-20,000 pg/mL), medium 
(1,000-4,000 pg/mL), and low (20-800 pg/mL) concentra­
tions of all 6 cytokines were run with each assay.
The 6 different monoclonal capture antibody-coupled 
microspheres were mixed together at a concentration of 1.0 
x 105 of each microsphere per milliliter. We added 50 [iL of 
the microsphere mixture to 100 of tissue culture super­
natant, cytokine standard, or control, resulting in a final 
concentration of 5,000 of each individual microsphere 
(30,000 total) per reaction. The cytokine standards, controls, 
tissue culture supernatants, and microspheres were incu­
bated for 20 minutes at room temperature using a foil- 
covered, 96-well filter bottom microtiter plate (Millipore, 
Bedford, MA) on a shaker. The microspheres then were 
washed 3 times with 200 ^L of PBST by vacuum filtration 
of the microtiter plate. This was followed by the addition of 
100 of biotinylated polyclonal antibodies to human IL-4, 
1L-6,1L-10 (BD Biosciences), 1L-12 (R&D Systems), 1L-2, 
and IFN-gamma (Pierce-Endogen) to each well of the
microtiter plate. The final concentration of the biotinylated 
detection antibodies ranged from 1 to 3 ng/mL. Following a 
second 20-minute incubation on the shaker, the microtiter 
plate was washed as before, and 100 ^L of 10 ng/mL of 
streptavidin-conjugated R-phycoerythrin (Molecular Probes, 
Eugene, OR) was added to each well. After a 10-minute 
incubation and final wash, the microspheres were resus­
pended in 100 of PBST. The 96-w ell m icroplate 
containing the resuspended microspheres was placed in a 
Luminex 100 instrument with an XY platform (automated 
microtiter plate handler), where the microspheres were 
counted and analyzed. The amount of cytokine bound to the 
microspheres by this antibody sandwich technique is deter­
mined by the median fluorescence intensity of the reporter 
molecule phycoerythrin. When excited at 532 nm, phyco- 
erythrin emits at 575 nm. The median fluorescence intensity 
of the unknown sample then is converted into a value 
(pg/mL) based on the known cytokine concentrations of the 
standard curve using a 5-parameter regression formula. 
Since the analyte specificity and position of each micro­
sphere classification in the array is known, a single fluores­
cent reporter molecule can be used to measure all 6 cytokine 
concentrations.
R e s u l t s
Validation of the Multiplexed Assay
Linearity and percentage of recovery of the multiplexed 
cytokine assay were assessed by spiking known concentra­
tions of recombinant human cytokines in diluted RPMI 
medium and using actual patient samples containing native 
cytokines. For the spiked sample, all 6 cytokines were mixed 
together in concentrations ranging from 6,000 to 30,000 
pg/mL. This sample then was serially diluted and run in 
duplicate in the multiplexed assay containing reagents for all
6  cytokines. The mean observed value was obtained by aver­
aging the duplicate values (pg/mL), while the expected value 
was calculated from the known starting amount of spiked 
material. Linear regression analysis then was used to calcu­
late slope, y-intercept, and R2 for observed vs expected 
values. Percentage of recovery was calculated by dividing 
the mean observed value by the expected value. The linear 
regression recombinant spiking results for the 6 cytokines 
are shown in IFigure II. Mean ± SD recoveries for the 
recombinant cytokines in the multiplex assay were good 
(104% ± 17%), ranging from a low of 79% for 1L-12 to a 
high of 126% for IL-6 ITable II. To ensure that the capture 
and secondary antibodies used in the assay also recognized 
native human cytokines, similar studies were done using 
patient tissue culture supernatants obtained from stimulated
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Expected Cytokine Concentration (pg/mL)
IFigure II Linear regression analysis of expected vs 
observed values (pg/mL) for a single sample spiked with 
known concentrations of 6 recombinant human cytokines. 
IFN, interferon; IL, interleukin.
peripheral blood mononuclear cells. Tissue culture super­
natant derived from several patients* stimulated peripheral 
blood mononuclear cells was diluted serially and ran in the 
multiplexed assay. Linear regression analysis and percentage 
of recovery then was calculated as before. Percentages of 
recovery for the native cytokines were similar to those for 
the recombinant cytokines, with a mean ± SD of 101% ± 
17%, ranging from 88% for IL-10 to 131% for IFN-gamma 
(Table 1). A patient sample with sufficiently high concentra­
tions of 1L-4 was unavailable and, therefore, was not 
included in the native cytokine linearity studies.
Sensitivity was determined by measuring the lowest 
concentration of cytokine that could be differentiated reliably 
from zero in the Luminex multiplex format. This was deter­
mined by statistical comparison of variation of the lowest
standard (7.2 pg/mL) with samples containing no analyte.16 
After measuring cytokine concentrations in the RPM1 
medium blanks in replicates of 10 by 3 different reagent lots, 
sensitivities at 95% confidence intervals (+ 2 SD) were 
determined as follows; 5.1 pg/mL for IL-2, 3.4 pg/mL for 
IL-4, 5.7 pg/mL for IL-6, 4.5 pg/mL for IL-10, 5.2 pg/mL 
for IL-12, and 6.4 pg/mL for IFN-gamma.
To study the specificity of the monoclonal antibodies 
coupled to the microspheres in a multiplexed format, high 
concentrations of only 1 cytokine were spiked into assay 
diluent to create 6 different samples. These samples then 
were run in the multiplexed format to check for cross-reac­
tivity of the assay ITable 21. Some cross-reactivity was seen 
between IFN-gamma and the other cytokines, most notably 
with IL-12. In some cases, matched antibody pairs (usually 
a monoclonal capture antibody and biotinylated polyclonal 
secondary antibody) available from commercial vendors did 
not perform optimally in the Luminex platform. Initial 
development of the IL-2 assay was done using a matched 
antibody pair and recombinant human IL-2 from R&D 
Systems. The antibody pair showed a good specific reaction 
to a sample spiked with 10,000 pg/mL of IL-2 cytokine but 
had high background at 0 pg/mL of IL-2 cytokine. For this 
reason, 2 other matched antibody pairs from Pierce- 
Endogen and BD Biosciences were studied. The 3 different 
vendors* capture antibodies and biotinylated detection anti­
bodies were cross-tested against each other to find the 
optimal antibody pair. When the Pierce-Endogen capture 
antibody was matched with the Pierce-Endogen detection 
body, background (0 pg/mL) was minimal, but there was 
also no specific response at 10,000 pg/mL. In fact, the 
Pierce-Endogen capture antibody did not give a specific 
response when matched to any of the 3 detection antibodies 
and, therefore, probably did not recognize the recombinant 
IL-2 from R&D Systems. Good specific signal/background
ITable II
Summary of Regression Analysis and Percentage Recoveries of the Expected vs Observed Values (pg/mL) for Interleukins 2,6,10, 
and 12, and Interferon-gamma Obtained From a Sample Spiked With Known Concentrations of Recombinant Human Cytokines 
and From Supernatants Containing Native Human Cytokines'
Cytokine Source Slope y-In tereep t R 1 M ean ± SD R ecovery (% )
Interleukin
2 R ecom binan t 0.99 74.9 0 .999 108 ± 8
Native 1.11 -2 3 .2 0 .993 9 6  ± 10
4 R ecom binan t 1.03 85.7 0 .997 114 ± 11
6 R ecom binan t 1.11 159.6 0 .998 126 ± 8
Native 0.97 -1 .8 1.000 94  ± 4
10 R ecom binan t 0.92 137.2 0 .998 109 ± 14
Native 0.88 0.7 0 .999 88  ± 4
12 R ecom binan t 1.06 -5 0 6 .6 0 .993 79 ± 14
Native 1.04 -9 .1 0 .997 9 6  ± 6
In terferon-gam m a R ecom binan t 1.06 -2 7 .3 1.000 97  ± 13
Native 1.79 -1 7 0 .5 0 .989 131 ± 28
* A sufficient sample of native IL-4 was not available.
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ITable 21
Results of Specificity Studies in Which Six Different Samples Were Spiked With High Concentrations of Only One Cytokine 
and Assayed in the Six-Cytokine Multiplexed Format
Luminex’' Results (pg/mL)
Sample Spiked With IL-2 IL-4 IL-6 IL-10 IL-12 IFN-gamma
1 IL-2 18,905 0 0 0 0 0
2 IL-4 0 9 ,546 3 0 0 0
3 IL-6 0 0 20,163 0 0 0
4 IL-10 0 0 0 13,753 0 0
5 IL-12 0 0 0 0 22 ,562 0
6 IFN -gam m a 9 2 15 4 64 12,409
IFN, interferon; IL, interleukin,
* For proprietary information, see the text.
ratios were achieved when using the BD Biosciences 
capture antibody and any of the 3 secondary antibodies, 
with the best signal/background ratio obtained using the BD 
Biosciences capture antibody, the biotinylated secondary 
antibody from Pierce-Endogen, and the recombinant human 
IL-2 from R&D Systems.
Precision of the 6-cytokine multiplexed assay was deter­
mined by intra-assay and interassay studies on 3 different 
reagent lots using the high, medium, and low assay controls. 
A lot was defined as independent coupling reactions of the
monoclonal capture antibodies to the microspheres and sepa­
rated preparations of the secondaiy conjugated polyclonal 
antibodies. For intra-assay precision, the mean, SD, and 
coefficient of variation (C.V) were calculated from 5 repli­
cates of each level of control. Data from a typical run and lot 
show CVs of mostly less than 10% ITable 31. For interassay 
precision, the mean, SD, and C.V percentage were calculated 
from 2 runs each on 3 different lots, for a total of 6 runs. CVs 
ranged from less than 15% for the high control to up to 30% 
for the low control (Table 3).
ITable 31
Intra-assay Precision Results for the Six-Cytokine Multiplexed Assay for a Typical Reagent Lot (n = 5) and Interassay Precision 
Results Obtained From Two Runs on Three Different Reagent Lots (n = 6) '
IL-2 IL-4 IL-6 IL-10 IL-12 IFN-gamma
In tra-assay  re su lts  
High control
M ean 7 4 2 6 .3 567.0 13,668.7 15,824.0 14,255.5 6 ,473 .4
SD 341.9 36.8 167.8 1211.2 280.6 383 .6
CV 4.6 6.5 1.2 7.7 2.0 5.9
M edium  control
M ean 321.4 25.8 659 .6 862 .8 718.6 587.4
SD 21.8 2.4 19.8 77.5 32.0 59.4
CV 6.8 9.3 3.0 9.0 4.5 10.1
Low control
M ean 19.3 5.5 50.3 59.3 50.2 39.5
SD 1.5 0.1 3.1 5.2 3.0 2.6
CV 7.8 2.2 6.2 8.8 6.0 6.6
In te ra ssa y  re su lts  
High control
M ean 7 2 2 2 .3 639.0 13,653.2 15,359.5 14,364.9 6 ,078 .8
SD 820.1 79.4 1,831.2 1,429.0 664 .6 690.0
CV 11.4 12.4 13.4 9.3 4.6 11.4
M edium  control
M ean 329 .8 40.5 701.3 884 .7 708 .4 534.4
SD 44.4 11.0 105.6 105.7 49.0 110.0
CV 13.5 272 15.1 12.0 6.9 20.6
Low control
M ean 34.1 2.7 71.7 80.5 69 .7 62.3
SD 6.2 2.6 21.3 19.4 21.3 19.0
CV 18.2 94.3 29.7 24.1 30.6 30 .5
IFN, interferon; IL, interleukin,
* Mean and SD values are given in picograms per milliliter. The coefficients of variations (CV) are given as percentages.
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Cytokine Responses of Patients and Neonates With 
Hyperimmunoglobulinemia E Syndrome
To validate the clinical usefulness of the 6-cytokine 
multiplexed assay, cytokine concentrations in tissue culture 
supernatant derived from stimulated mononuclear cells of 
patients with hyperimmunoglobulinemia E syndrome and 
neonates were assessed.
The production of cytokines IL-2, IL-4, IL-6, IL-10, IL- 
12, and IFN-gamma by 6 patients with hyperimmunoglobu- 
linemia E syndrome and the peripheral blood mononuclear 
cells of 12 control subjects in response to S aureus, one of the 
major pathogens affecting the patients, and medium alone 
was measured. We found no statistically significant differ­
ences in cytokine production in medium alone between 
patients and control subjects for any of the 6 cytokines 
measured. When comparing the cytokine production of 
patients and control subjects in response to stimulated periph­
eral blood mononuclear cells, the average concentrations of 
IL-6, IL-10, and IL-12 were lower in patients than in control 
subjects, but the differences were not statistically significant 
IFigure 21. The average IFN-gamma production of S 
a//re/«-stimulated control samples (304 pg/mL) vs patient 
samples (20 pg/mL) was, however, statistically different 
using a 2-tailed, unpaired t test (P = .044) (Figure 2).
Unstimulated (medium alone) and group B streptococci- 
stimulated neonatal cord blood-derived mixed mononuclear 
cells showed no statistically significant differences in IL-2,
IL-4, IL-10, IL-12, or IFN-gamma cytokine production after 
48-hour culture incubations. The cord blood cells produced 
significant concentrations of IL-6 when stimulated with 
group B streptococci (mean, 30,957 pg/mL) compared with 
the unstimulated cells (mean, 182 pg/mL) (P = .001) IFigure 
31. Adult group B streptococci-stimulated peripheral blood 
mononuclear cells released significantly greater concentra­
tions of IFN-gamma, IL-12, and IL-6 compared with 
unstimulated adult cells (Figure 3). After 48-hour culture 
incubations, the average IFN-gamma production for 
unstimulated adult cells was 0 pg/mL compared with 118 
pg/mL for group B streptococci-stimulated adult cells and 
was statistically significant (P = .017). For IL-12, the 
average cytokine production for unstimulated adult cells 
was 6.7 pg/mL compared with 51.3 pg/mL for group B 
streptococci-stimulated adult cells and was statistically 
significant (P = .007; 2-tailed, unpaired t test). The average 
IL-6 production for unstimulated adult cells was 317 pg/mL 
com pared w ith 19,789 pg/m L for group B strepto- 
cocci-stimulated adult cells and was statistically significant 
(P = .0003).
Neonatal group B streptococci-stimulated cells also 
produced significantly less IFN-gamma and IL-12 than did 
the stimulated adult cells. The average IFN-gamma cytokine 
production for neonatal cells was 1.2 pg/mL compared with 
118.6 pg/mL for the adults* group B streptococci-stimulated 
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■Figure 21 Mean cytokine production by mixed peripheral blood 
mononuclear cells of 12 healthy control subjects (black bars) 
and 6 patients with hyperimmunoglobulinemia E syndrome 
(white bars) in response to Staphylococcus aureus showing a 
significant decrease in interferon (IFN)-gamma production (P = 








□  Neonate Unstimulated
□  Neonate Stimulated
□  Adult Unstimulated 
■  Aduit Stimulated
IFN-y IL-12 IL-6
IFigure 31 Mean interferon (IFN)-gamma, interleukin (IL)-2 and 
ILr6 cytokine production by mixed mononuclear cells of 8 adult 
control subjects and 8 neonates in response to group B 
streptococci. Results show no significant IFN-gamma and IL-12 
production in stimulated vs unstimulated neonatal cells and 
significantly less IFN-gamma and IL-12 production in stimulated 
neonatal vs adult cells. ” P< .05, stimulated vs unstimulated 
cells.f P< .05, adult stimulated vs neonatal stimulated cells.
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production, in which die stimulated neonatal cells produced 
significantly less cytokine than did the adults’ stimulated 
cells (13.5 vs 51.3 pg/mL; P = .017; Figure 3).
D i s c u s s i o n
An assay with a large dynamic range is needed for 
measuring cytokine concentrations because of the varied and 
widely ranging cytokine responses generated by antigen- and 
mitogen-stimulated peripheral blood mononuclear cells of 
immunodeficient patients and healthy control subjects. This 
is especially tine when working with tissue culture super- 
natants in which the sample volume usually is insufficient for 
multiple dilutions, and repeated assay inns often are required 
to determine a final result for samples having high cytokine 
concentrations.
Standard curves developed by diluting recombinant 
cytokines over a 4- to 5-logarithmic range of concentration 
produced a reportable range of less than 10 to 50,000 pg/mL 
for all 6 multiplexed cytokines. To generate this large 
dynamic range, washing of the microspheres between 
reagent additions was necessary to reduce background fluo­
rescence to achieve maximum sensitivity. The use of a 5- 
parameter curve fit also contributed to the large dynamic 
range. By conducting linearity studies using spiked recombi­
nant cytokine samples and peripheral blood mononuclear 
cell-stimulated patient samples, both the high end (up to 
30,000 pg/mL) and low end (down to 14 pg/mL) of the 
reportable range of the assay was studied. This also ensured 
that the assay could accurately quantitate both recombinant 
and native human cytokines. Mean ± SD recoveries for the 
recombinant cytokines in the multiplex assay were good 
(104% ± 17%) and ranged from a low of 79% for IL-12 to a 
high of 126% for IL-6 (Table 1). These findings were veiy 
similar to published results of Kellar et al,17 who reported 
percentages of recovery ranging from 79 to 122 for 2 multi­
plexed assays for the quantitation of 4 cytokines each.
In our assay, die cytokine with the lowest percentage of 
recovery (IL-12) also showed die highest amount of cross-reac­
tivity with IFN-gamma (Table 2). Percentage of recovery results 
for the lower end of the reportable range of the assay using 
native cytokines from tissue culture supernatant were similar to 
our recombinant spiked sample studies. Recoveries ranged from 
88% for IL-10 to 131% for IFN-gamma, widi an overall mean ± 
SD of 101% ± 17%. The sensitivity or detection limit for die 6- 
cytokine multiplexed assay was less than 10 pg/mL for all 
cytokines, widi a mean ± SD of 5.1 ± 1 pg/mL. These sensitivi­
ties are equivalent to diose of most ELISAs and were lower dian 
those reported by Kellar et al17 for their Luminex-based, 4- 
cytokine multiplexed assays. For die same 6 cytokines, Kellar et 
al17 reported an average sensitivity of 10.8 pg/mL for their low
sensitivity (1,000-bead) assay. The increase in sensitivity of 
the assay described herein is probably due to the washing 
steps used in our protocol, which remove any unbound or 
excess cytokine, conjugate, and fluorescent reporter that can 
increase background signal. In experiments in which the 
same multiplexed assay was ran widiout washing, the fluores­
cence intensity values for the high standard (50,000 pg/mL) 
were decreased by up to 58%, while die 0 cytokine standard 
(background) had up to a 531% increase in fluorescence 
intensity units compared with the washed assay results (data 
not shown). The use of washing steps also reduces the 
amount of initial optimization required to obtain the correct 
concentration of capture antibodies, biotinylated secondary 
antibodies, and reporter fluorochrome, and reoptimization is 
not required between preparations of coupled microspheres. 
A disadvantage of washing is that it increases manual labor 
by 12 to 15 minutes per assay ran and the reagent cost by $9 
for the Millipore 96-well filtration plate.
Owing to the multiplexed format of this assay, in which 
multiple cytokines and capture and detection antibodies are 
present in the same reaction mixture, cross-reactivity 
becomes a much greater issue than with ELISAs, in which 
the measurement of each cytokine is done in separate reac­
tion wells. For the development of a sensitive and specific 
assay, the selection of good antibody pairs is, therefore, 
crucial. Fortunately, there are many commercial vendors 
offering “matched” antibody pairs designed specifically for 
ELISA development. In our experience, these matched anti­
body pairs generally have worked well when used with the 
Luminex platform. A notable exception was in the develop­
ment of the IL-2 assay, in which the best specific 
signal/background ratios were obtained using the BD 
Biosciences capture antibody, recombinant IL-2 from R&D 
Systems, and the Pierce-Endogen secondary antibody.
Results from the Luminex instrument showed a high 
degree of precision in both intra-assay and interassay studies 
(Table 3). In the multiplexed cytokine assay, the Luminex 
instrument was set to count 200 microspheres of each 
cytokine, for a total of at least 1,200 analyzed microspheres 
for each reaction well. The final reported result (in pg/mL) 
is, therefore, the median value of at least 200 analyzed 
microspheres for each cytokine. Since each individual 
microsphere is in essence its own immunoassay, this would 
be analogous to testing each individual patient sample in 
replicates of 200 in an ELISA for each individually 
measured cytokine. It is this measure of redundancy that 
gives the Luminex instrument its high level of precision.
The clinical usefulness of the 6-cytokine multiplexed 
assay was demonstrated by measuring cytokine concentra­
tions in tissue culture supernatant derived from stimulated 
mononuclear cells of immunodeficient patients and neonates. 
The S a//re/«-stimulated peripheral blood mononuclear cells
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from 6 patients with diagnosed hyperimmimoglobulinemia E 
syndrome had significantly lower IFN-gamma production 
than samples from healthy control subjects. These observa­
tions agree with those of Del Prete et al7 and Borges et al,2 
who found that cells from patients with hyperimmunoglobu- 
linemia E syndrome failed to make adequate amounts of IFN- 
gamma. IFN-gamma and IL-12 production by mixed 
mononuclear cells derived from neonatal cord blood was 
significantly less than that of adult cells when stimulated with 
group B streptococci. These observations are consistent with 
reports by Joyner et al,8 Bryson et al,9 and Wilson et al,10 who 
reported deficient IFN-gamma and IL-12 production by 
neonates. Analysis of TH1- and TH2-type cytokine responses 
by the mononuclear cells of patients with these immunodefi­
ciency syndromes suggests a role for imbalances in the 
cytokine repertoire in selected diseases. These studies demon­
strate the potential of cytokine measurement in the clinical 
laboratory as a diagnostic tool for assessing immunodeficien­
cies or diseases known to result in depressed or defective 
cytokine production.
The multiplexing capability of the Luminex instrument 
is invaluable for the development of multiple analyte profiles 
that require smaller amounts of patient samples and reagents 
and less cost than traditional diagnostic methods. We found 
the Luminex instrument to be an accurate and reliable 
system for simultaneously quantitating 6 cytokines from 
only 100 nL of patient tissue culture supernatant. Because of 
the efficiency and lower costs of the multiplexed assay, 
cytokine testing is now more feasible to perform in a clinical 
laboratory setting. Studies are increasingly showing correla­
tions between cytokine production and immunologic inflam­
matory disorders and other disease processes. With the 
ability to measure multiple cytokines from a single sample 
source, we have a powerful research and clinical tool for 
assessing cytokines produced in cellular responses.
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